ConsumerLab sexual supplement review
This article was originally published in The Tan Sheet
Executive Summary
Nine of 22 sexual enhancement products (41%) pass 1ConsumerLab.com testing, online firm reports Sept. 24. Passing products, including six arginine and three yohimbe-based supplements, "were properly labeled, contained the claimed ingredients tested for and were not spiked with" Rx drug sildenafil, group says. Half the products were disqualified due to non-compliance with FDA labeling requirements, "such as incorrect or missing plant species names and/or no identification of the plant parts used," site explains. Several other supplements failed testing when they were found to contain significantly smaller percentage of active ingredient than claimed...
You may also be interested in...
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.